Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Rating Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of Arcutis Biotherapeutics (NASDAQ:ARQT) from a buy rating to a hold rating in a report published on Saturday morning,Wall Street Zen reports.

A number of other equities research analysts have also weighed in on the stock. Needham & Company LLC set a $40.00 target price on shares of Arcutis Biotherapeutics in a report on Thursday. Morgan Stanley raised their price target on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded shares of Arcutis Biotherapeutics from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 29th. TD Cowen lifted their price target on shares of Arcutis Biotherapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Guggenheim boosted their price objective on shares of Arcutis Biotherapeutics from $38.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, October 19th. Eight research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $39.75.

Arcutis Biotherapeutics Stock Performance

NASDAQ:ARQT opened at $25.55 on Friday. The stock has a market cap of $3.22 billion, a P/E ratio of 121.67 and a beta of 1.66. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 0.42. The stock’s 50-day moving average is $27.16 and its 200-day moving average is $25.37. Arcutis Biotherapeutics has a 1-year low of $19.30 and a 1-year high of $34.80.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.12). Arcutis Biotherapeutics had a net margin of 5.88% and a return on equity of 14.18%. The business had revenue of $143.92 million during the quarter, compared to the consensus estimate of $142.59 million. Equities research analysts anticipate that Arcutis Biotherapeutics will post 0.33 earnings per share for the current year.

Insider Buying and Selling at Arcutis Biotherapeutics

In other news, Director Howard G. Welgus sold 4,728 shares of Arcutis Biotherapeutics stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $26.93, for a total value of $127,325.04. Following the completion of the transaction, the director directly owned 35,207 shares of the company’s stock, valued at approximately $948,124.51. This trade represents a 11.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Terrie Curran sold 38,200 shares of the business’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $25.03, for a total value of $956,146.00. Following the completion of the transaction, the director directly owned 23,526 shares in the company, valued at $588,855.78. This represents a 61.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 123,932 shares of company stock valued at $3,553,077. 9.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arcutis Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Montanova Capital LLC lifted its stake in Arcutis Biotherapeutics by 0.9% in the second quarter. Montanova Capital LLC now owns 12,437,000 shares of the company’s stock valued at $326,098,000 after buying an additional 110,000 shares during the period. BlackRock Inc. acquired a new stake in shares of Arcutis Biotherapeutics during the 2nd quarter worth approximately $276,502,000. Bank of America Corp DE acquired a new stake in shares of Arcutis Biotherapeutics during the 2nd quarter worth approximately $78,330,000. Janus Henderson Group PLC grew its position in shares of Arcutis Biotherapeutics by 1.3% during the 1st quarter. Janus Henderson Group PLC now owns 1,854,566 shares of the company’s stock worth $43,684,000 after buying an additional 24,505 shares during the period. Finally, Jupiter Topco LLC bought a new stake in shares of Arcutis Biotherapeutics in the 2nd quarter valued at $36,989,000.

More Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis raised its 2026 sales guidance, a sign of improved commercial expectations. However, investors may be weighing whether the stronger outlook is already reflected in the stock. Article: Arcutis Biotherapeutics Raised 2026 Sales Guidance
• Positive Sentiment: The company began enrolling participants in a Phase 3 study of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the medicine’s potential market, though this remains a clinical-development catalyst. Article: Arcutis Begins Enrolling Phase 3 ZORYVE Study
• Neutral Sentiment: Arcutis granted stock options and restricted stock units to six new employees. The awards create some share dilution, but are routine hiring-related inducements and are not a major business update. Article: Arcutis Reports Inducement Grants
• Negative Sentiment: Third-quarter EPS was $0.06, below analyst expectations of roughly $0.17–$0.18. Revenue of $143.92 million narrowly topped forecasts, but the earnings miss appears to be the more immediate sentiment driver. Article: Arcutis Falls After Q3 Earnings Miss
• Negative Sentiment: HC Wainwright cut its EPS estimates for the first three quarters of 2027, including reducing its Q2 forecast from $0.19 to $0.14. The lowered projections add to concerns following the quarterly earnings shortfall.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.